Antineoplastic resistance

Last updated

Antineoplastic resistance, often used interchangeably with chemotherapy resistance, is the resistance of neoplastic (cancerous) cells, or the ability of cancer cells to survive and grow despite anti-cancer therapies. [1] In some cases, cancers can evolve resistance to multiple drugs, called multiple drug resistance.

Contents

There are two general causes of antineoplastic therapy failure: Inherent genetic characteristics, giving cancer cells their resistance and acquired resistance after drug exposure, which is rooted in the concept of cancer cell heterogeneity. [1] Characteristics of resistant cells include altered membrane transport, enhanced DNA repair, apoptotic pathway defects, alteration of target molecules, protein and pathway mechanisms, such as enzymatic deactivation. [1] Since cancer is a genetic disease, two genomic events underlie acquired drug resistance: Genome alterations (e.g. gene amplification and deletion) and epigenetic modifications. Cancer cells are constantly using a variety of tools, involving genes, proteins, and altered pathways, to ensure their survival against antineoplastic drugs.

Definition

Antineoplastic resistance, synonymous with chemotherapy resistance, is the ability of cancer cells to survive and grow despite different anti-cancer therapies, i.e. their multiple drug resistance. There are two general causes of antineoplastic therapy failure: [2] Inherent resistance, such as genetic characteristics, giving cancer cells their resistance from the beginning, which is rooted in the concept of cancer cell heterogeneity and acquired resistance after drug exposure. [2]

Cancer cell heterogeneity

Cancer cell heterogeneity, or tumour heterogeneity, is the idea that tumours are made up of different populations of cancer cells that are morphologically, phenotypically and functionally different. [3] Certain populations of cancer cells may possess inherent characteristics, such as genetic mutations and/or epigenetic changes, that confer drug resistance. Antineoplastic drugs kill susceptible sub-populations and the tumour mass may shrink as an initial response to the drug, resistant cancer cells will survive treatment, be selected and then propagate, eventually causing a cancer relapse.[ citation needed ]

Cancer cell heterogeneity can cause disease progression when molecularly targeted therapy, fails to kill those tumor cells which do not express the marker, then divide and mutate further, creating a new heterogeneous tumour. In breast cancer models of the mouse the immune microenvironment affects susceptibility to neoadjuvant chemotherapy. In breast cancer, particularly in the triple-negative subtype, immune checkpoint blockade has been used successfully in metastatic cases and neoadjuvant therapy. [4]

Acquired resistance

Since cancer is a genetic disease, [5] two genomic events underlie these mechanisms of acquired drug resistance: Genome alterations (e.g. gene amplification and deletion) and epigenetic modifications.

Genetic causes

Genome alterations

Chromosomal rearrangement due to genome instability can cause gene amplification and deletion. Gene amplification is the increase in copy number of a region of a chromosome. [6] which occur frequently in solid tumors, and can contribute to tumor evolution through altered gene expression. [6]

Hamster cell research in 1993 showed that amplifications in the DHFR gene involved in DNA synthesis began with chromosome break in below the gene, and subsequent cycles of bridge-breakage-fusion formations result in large intrachromosomal repeats. [7] The over amplification of oncogenes can occur in response to chemotherapy, thought to be the underlying mechanism in several classes of resistance. [6] For example, DHFR amplification occurs in response to methotrexate, [8] TYMS (involved in DNA synthesis) amplification occurs in response to 5-fluorouracil, [9] and BCR-ABL amplification occurs in response to imatinib mesylate. [10] Determining areas of gene amplification in cells from cancer patients has huge clinical implications. Gene deletion is the opposite of gene amplification, where a region of a chromosome is lost and drug resistance occurs by losing tumor suppressor genes such as TP53. [2]

Genomic instability can occur when the replication fork is disturbed or stalled in its migration. This can occur with replication fork barriers, proteins such as PTIP, CHD4 and PARP1, which are normally cleared by the cell's DNA damage sensors, surveyors, and responders BRCA1 and BRCA2. [11]

Epigenetic mechanisms

Epigenetic modifications in antineoplastic drug resistance play a major role in cancer development and drug resistance as they contribute to the regulation of gene expression. [12] Two main types of epigenetic control are DNA methylation and histone methylation/acetylation. DNA methylation is the process of adding methyl groups to DNA, usually in the upstream promoter regions, which stops DNA transcription at the region and effectively silences individual genes. Histone modifications, such as deacetylation, alters chromatin formation and silence large chromosomal regions. In cancer cells, where normal regulation of gene expression breaks down, the oncogenes are activated via hypomethylation and tumor suppressors are silenced via hypermethylation. Similarly, in drug resistance development, it has been suggested that epigenetic modifications can result in the activation and overexpression of pro-drug resistance genes. [12]

Studies on cancer cell lines have shown that hypomethylation (loss of methylation) of the MDR1 gene promoter caused overexpression and the multidrug resistance. [13]

In a methotrexate resistant breast cancer cell lines without drug uptake and folate carrier expression, giving DAC, a DNA methylation inhibitor, improved drug uptake and folate carrier expression. [14]

Acquired resistance to the alkylating drug fotemustine in melanoma cell showed high MGMT activity related to the hypermethylation of the MGMT gene exons. [15]

In Imatinib resistant cell lines, silencing of the SOCS-3 gene via methylation has been shown to cause STAT3 protein activation, which caused uncontrolled proliferation. [16]

Cancer cell mechanisms

Cancer cells can become resistant to multiple drugs by altered membrane transport, enhanced DNA repair, apoptotic pathway defects, alteration of target molecules, protein and pathway mechanisms, such as enzymatic deactivation. [12]

Altered membrane transport

An overview of antineoplastic resistance mechanisms, and examples of the major genes involved. Blue boxes indicate cancer cell proliferation mechanisms; green boxes indicate therapeutic interventions; red boxes indicate resistance mechanisms. Antineoplastic resistances.png
An overview of antineoplastic resistance mechanisms, and examples of the major genes involved. Blue boxes indicate cancer cell proliferation mechanisms; green boxes indicate therapeutic interventions; red boxes indicate resistance mechanisms.

Many classes of antineoplastic drugs act on intracellular components and pathways, like DNA, nuclear components, meaning that they need to enter the cancer cells. The p-glycoprotein (P-gp), or the multiple drug resistance protein, is a phosphorylated and glycosylated membrane transporter that can shuttle drugs out of the cell, thereby decreasing or ablating drug efficacy. This transporter protein is encoded by the MDR1 gene and is also called the ATP-binding cassette (ABC) protein. MDR1 has promiscuous substrate specificity, allowing it to transport many structurally diverse compounds across the cell membrane, mainly hydrophobic compounds. Studies have found that the MDR1 gene can be activated and overexpressed in response to pharmaceutical drugs, thus forming the basis for resistance to many drugs. [2] Overexpression of the MDR1 gene in cancer cells is used to keep intracellular levels of antineoplastic drugs below cell-killing levels.[ citation needed ]

For example, the antibiotic rifampicin has been found to induce MDR1 expression. Experiments in different drug resistant cell lines and patient DNA revealed gene rearrangements which had initiated the activation or overexpression of MDR1. [17] A C3435T polymorphism in exon 226 of MDR1 has also been strongly correlated with p-glycoprotein activities. [18]

MDR1 is activated through NF-κB, a protein complex which acts as a transcription factor. [19] [20] [21] [22] In the rat, an NF-κB binding site is adjacent to the mdr1b gene, [23] NF-κB can be active in tumour cells because its mutated NF-κB gene or its inhibitory IκB gene mutated under chemotherapy. In colorectal cancer cells, inhibition of NF-κB or MDR1 caused increased apoptosis in response to a chemotherapeutic agent. [19]

Enhanced DNA repair

Enhanced DNA repair plays an important role in the ability for cancer cells to overcome drug-induced DNA damages.

Platinum-based chemotherapies, such as cisplatin, target tumour cells by cross-linking their DNA strands, causing mutation and damage. [2] Such damage will trigger programmed cell death (e.g. apoptosis) in cancer cells. Cisplatin resistance occurs when cancer cells develop an enhanced ability to reverse such damage by removing the cisplatin from DNA and repairing any damage done. [2] [12] The cisplatin-resistant cells upregulate expression of the excision repair cross-complementing (ERCC1) gene and protein. [2]

Some chemotherapies are alkylating agents meaning they attach an alkyl group to DNA to stop it from being read. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme which removes alkyl groups from DNA. MGMT expression is upregulated in many cancer cells, which protects them from alkylating agents. [12] Increased MGMT expression has been found in colon cancer, lung cancer, non-Hodgkin's lymphoma, breast cancer, gliomas, myeloma and pancreatic cancer. [24]

Apoptotic pathway defects

TP53 is a tumor suppressor gene encoding the p53 protein, which responds to DNA damage either by DNA repair, cell cycle arrest, or apoptosis. Losing TP53 via gene deletion can allow cells to continuously replicate despite DNA damage. The tolerance of DNA damage can grant cancer cells a method of resistance to those drugs which normally induce apoptosis through DNA damage. [2] [12]

Other genes involved in the apoptotic pathway related drug resistance include h-ras and bcl-2/bax. [25] Oncogenic h-ras has been found to increase expression of ERCC1, resulting in enhanced DNA repair (see above). [26] Inhibition of h-ras was found to increase cisplatin sensitivity in glioblastoma cells. [27] Upregulated expression of Bcl-2 in leukemic cells (non-Hodgkin's lymphoma) resulted in decreased levels of apoptosis in response to chemotherapeutic agents, as Bcl-2 is a pro-survival oncogene. [28]

Altered target molecules

During targeted therapy, oftentimes the target has modified itself and decreased its expression to the point that therapy is no longer effective. One example of this is the loss of estrogen receptor (ER) and progesterone receptor (PR) upon anti-estrogen treatment of breast cancer. [29] Tumors with loss of ER and PR no longer respond to tamoxifen or other anti-estrogen treatments, and while cancer cells remain somewhat responsive to estrogen synthesis inhibitors, they eventually become unresponsive to endocrine manipulation and no longer dependent on estrogen for growth. [29]

Another line of therapeutics used for treating breast cancer is targeting of kinases like human epidermal growth factor receptor 2 (HER2) from the EGFR family. Mutations often occur in the HER2 gene upon treatment with an inhibitor, with about 50% of patients with lung cancer found to have an EGFR-T790M gatekeeper mutation. [12]

Treatment of chronic myeloid leukemia (CML) involves a tyrosine kinase inhibitor that targets the BCR/ABL fusion gene called imatinib. In some people resistant to Imatinib, the BCR/ABL gene is reactivated or amplified, or a single point mutation has occurred on the gene. These point mutations enhance autophosphorylation of the BCR-ABL protein, resulting in the stabilization of the ATP-binding site into its active form, which cannot be bound by imatinib for proper drug activation. [30]

Topoisomerase is a lucrative target for cancer therapy due to its critical role as an enzyme in DNA replication, and many topoisomerase inhibitors have been made. [31] Resistance can occur when topoisomerase levels are decreased, or when different isoforms of topoisomerase are differentially distributed within the cell. Mutant enzymes have also been reported in patient leukemic cells, as well as mutations in other cancers that confer resistance to topoisomerase inhibitors. [31]

Altered metabolism

One of the mechanisms of antineoplastic resistance is over-expression of drug-metabolizing enzymes or carrier molecules. [2] By increasing expression of metabolic enzymes, drugs are more rapidly converted to drug conjugates or inactive forms that can then be excreted. For example, increased expression of glutathione promotes drug resistance, as the electrophilic properties of glutathione allow it to react with cytotoxic agents, inactivating them. [32] In some cases, decreased expression or loss of expression of drug-metabolising enzymes confers resistance, as the enzymes are needed to process a drug from an inactive form to an active form. Arabinoside, a commonly used chemotherapy for leukemia and lymphomas, is converted into cytosine arabinoside triphosphate by deoxycytidine kinase. Mutation of deoxycytidine kinase or loss of expression results in resistance to arabinoside. [2] This is a form of enzymatic deactivation.[ citation needed ]

Growth factor expression levels can also promote resistance to antineoplastic therapies. [2] In breast cancer, drug resistant cells were found to express high levels of IL-6, while sensitive cells did not express significant levels of the growth factor. IL-6 activates the CCAAT enhancer-binding protein transcription factors which activate MDR1 gene expression (see Alteration of Membrane Transport). [33]

Genetic markers for drug sensitivity and resistance

Pharmacogenetics play an increasingly important role in antineoplastic treatment. [34] Rapid sequencing technologies can identify genetic markers for treatment sensitivity and potential resistance. Certain markers are more representative and more likely to be used clinically. [34]

When BRCA1 and BRCA2 are missing, as in 5 percent to 10 percent of all breast cancers, a stalled fork remains destabilized and its newly synthesized DNA is degraded. This genomic instability means the cancer cell is actually more sensitive to DNA-damaging chemotherapy drugs. [35]

Characteristics of Pharmacogenetic Tests [34]
MarkerDrugMajor ConditionsClinical Implications
TYMS 5-Fluorouracil Colorectal, stomach, pancreatic cancer High TYMS may show poor response & less toxicity
DPYD 5-Fluorouracil Colorectal, stomach, pancreatic cancer DPD deficiency associated with higher risk of toxicity
UGT1A1 Irinotecan Colorectal cancer Decreased UGT1A1 activity may increase risk of toxicity
CYP2D6 Tamoxifen Breast cancer Patients with deficient CYP2D6 activity are at greater risks of relapse
EGFR Anti-EGFR therapy Colorectal, lung cancer Activation of EGFR pathways enhances tumor growth, progression, & resistance to therapy
KRAS Anti-EGFR therapy Colorectal, lung cancer KRAS mutation is associated with resistance to anti-EGFR therapy
FCGR3A Rituximab Non-Hodgkin's lymphoma FCRG3A 158Val/Val genotype may be associated with better response
BRCA1/BRCA2 Platinum Breast, ovarian cancer BRCA1/2-mutated cancers are more sensitive to DNA damage. Secondary intragenic mutations confer acquired resistance

Genetic approaches to overcome drug resistance

MDR proteins are known to be drug-resistance genes, and are highly expressed in various cancers. Inhibition of the MDR genes could result in sensitization of cells to therapeutics and a decrease in antineoplastic resistance. Reversin 121 (R121) is a high-affinity peptide for MDR, and use of R121 as a treatment for pancreatic cancer cells results in increased chemosensitivity and decreased proliferation. [36]

Aberrant NF-κB expression is found in many cancers, and NF-κB has been found to be involved in resistance to platinum-based chemotherapies, such as cisplatin. NF-κB inhibition by genistein in various cancer cell lines (prostate, breast, lung and pancreas) showed increased growth inhibition and an increase in chemosensitivity, seen as an increase in apoptosis induced by therapeutic agents. [37] However, targeting the NF-κB pathway can be difficult, as there can be many off-target and non-specific effects.

Expression of mutated TP53 causes defects in the apoptotic pathway, allowing cancerous cells to avoid death. Re-expression of the wild-type gene in cancer cells in vitro has been shown to inhibit cell proliferation, induce cell cycle arrest and apoptosis. [38]

In ovarian cancer, the ATP7B gene encodes for a copper efflux transporter, found to be upregulated in cisplatin-resistant cell lines and tumors. Development of antisense deoxynucleotides against ATP7B mRNA and treatment of an ovarian cancer cell line shows that inhibition of ATP7B increases sensitivity of the cells to cisplatin. [39]

Related Research Articles

<span class="mw-page-title-main">Chemotherapy</span> Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

<span class="mw-page-title-main">Philadelphia chromosome</span> Genetic abnormality in leukemia cancer cells

The Philadelphia chromosome or Philadelphia translocation (Ph) is a specific genetic abnormality in chromosome 22 of leukemia cancer cells. This chromosome is defective and unusually short because of reciprocal translocation, t(9;22)(q34;q11), of genetic material between chromosome 9 and chromosome 22, and contains a fusion gene called BCR-ABL1. This gene is the ABL1 gene of chromosome 9 juxtaposed onto the breakpoint cluster region BCR gene of chromosome 22, coding for a hybrid protein: a tyrosine kinase signaling protein that is "always on", causing the cell to divide uncontrollably by interrupting the stability of the genome and impairing various signaling pathways governing the cell cycle.

<span class="mw-page-title-main">Cisplatin</span> Pharmaceutical drug

Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein.

<span class="mw-page-title-main">P-glycoprotein</span> Mammalian protein found in Homo sapiens

P-glycoprotein 1 also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of differentiation 243 (CD243) is an important protein of the cell membrane that pumps many foreign substances out of cells. More formally, it is an ATP-dependent efflux pump with broad substrate specificity. It exists in animals, fungi, and bacteria, and it likely evolved as a defense mechanism against harmful substances.

<span class="mw-page-title-main">NF-κB</span> Nuclear transcriptional activator that binds to enhancer elements in many different cell types

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a protein complex that controls transcription of DNA, cytokine production and cell survival. NF-κB is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. NF-κB plays a key role in regulating the immune response to infection. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF-κB has also been implicated in processes of synaptic plasticity and memory.

<span class="mw-page-title-main">Methyltransferase</span> Group of methylating enzymes

Methyltransferases are a large group of enzymes that all methylate their substrates but can be split into several subclasses based on their structural features. The most common class of methyltransferases is class I, all of which contain a Rossmann fold for binding S-Adenosyl methionine (SAM). Class II methyltransferases contain a SET domain, which are exemplified by SET domain histone methyltransferases, and class III methyltransferases, which are membrane associated. Methyltransferases can also be grouped as different types utilizing different substrates in methyl transfer reactions. These types include protein methyltransferases, DNA/RNA methyltransferases, natural product methyltransferases, and non-SAM dependent methyltransferases. SAM is the classical methyl donor for methyltransferases, however, examples of other methyl donors are seen in nature. The general mechanism for methyl transfer is a SN2-like nucleophilic attack where the methionine sulfur serves as the leaving group and the methyl group attached to it acts as the electrophile that transfers the methyl group to the enzyme substrate. SAM is converted to S-Adenosyl homocysteine (SAH) during this process. The breaking of the SAM-methyl bond and the formation of the substrate-methyl bond happen nearly simultaneously. These enzymatic reactions are found in many pathways and are implicated in genetic diseases, cancer, and metabolic diseases. Another type of methyl transfer is the radical S-Adenosyl methionine (SAM) which is the methylation of unactivated carbon atoms in primary metabolites, proteins, lipids, and RNA.

Zbtb7, whose protein product is also known as Pokemon, is a gene that functions as a regulator of cellular growth and a proto oncogene.

<span class="mw-page-title-main">Satraplatin</span> Chemical compound

Satraplatin is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

<span class="mw-page-title-main">RELA</span> Protein-coding gene in the species Homo sapiens

Transcription factor p65 also known as nuclear factor NF-kappa-B p65 subunit is a protein that in humans is encoded by the RELA gene.

A metastasis suppressor is a protein that acts to slow or prevent metastases from spreading in the body of an organism with cancer. Metastasis is one of the most lethal cancer processes. This process is responsible for about ninety percent of human cancer deaths. Proteins that act to slow or prevent metastases are different from those that act to suppress tumor growth. Genes for about a dozen such proteins are known in humans and other animals.

Somatic evolution is the accumulation of mutations and epimutations in somatic cells during a lifetime, and the effects of those mutations and epimutations on the fitness of those cells. This evolutionary process has first been shown by the studies of Bert Vogelstein in colon cancer. Somatic evolution is important in the process of aging as well as the development of some diseases, including cancer.

<span class="mw-page-title-main">Extranodal NK/T-cell lymphoma, nasal type</span> Medical condition

Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) is a rare type of lymphoma that commonly involves midline areas of the nasal cavity, oral cavity, and/or pharynx At these sites, the disease often takes the form of massive, necrotic, and extremely disfiguring lesions. However, ENKTCL-NT can also involve the eye, larynx, lung, gastrointestinal tract, skin, and various other tissues. ENKTCL-NT mainly affects adults; it is relatively common in Asia and to lesser extents Mexico, Central America, and South America but is rare in Europe and North America. In Korea, ENKTCL-NT often involves the skin and is reported to be the most common form of cutaneous lymphoma after mycosis fungoides.

Gene expression profiling has revealed that diffuse large B-cell lymphoma (DLBCL) is composed of at least 3 different sub-groups, each having distinct oncogenic mechanisms that respond to therapies in different ways. Germinal Center B-Cell like (GCB) DLBCLs appear to arise from normal germinal center B cells, while Activated B-cell like (ABC) DLBCLs are thought to arise from postgerminal center B cells that are arrested during plasmacytic differentiation. The differences in gene expression between GCB DLBCL and ABC DLBCL are as vast as the differences between distinct types of leukemia, but these conditions have historically been grouped together and treated as the same disease.

<span class="mw-page-title-main">Temozolomide</span> Medication for some brain cancers

Temozolomide (TMZ), sold under the brand name Temodar among others, is a medication used to treat brain tumors such as glioblastoma and anaplastic astrocytoma. It is taken by mouth or via intravenous infusion.

<span class="mw-page-title-main">Withaferin A</span> Chemical compound

Withaferin A is a steroidal lactone, derived from Acnistus arborescens, Withania somnifera and other members of family Solanaceae. It has been traditionally used in ayurvedic medicine. It is the first member of the withanolide class of ergostane type product to be discovered. This natural product has wide range of pharmacological activities including cardioprotective, anti-inflammatory, immuno-modulatory, anti-angiogenesis, anti-metastasis and anti-carcinogenic properties.

Platinum-based antineoplastic drugs are chemotherapeutic agents used to treat cancer. Their active moieties are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence.

Ionizing radiation can cause biological effects which are passed on to offspring through the epigenome. The effects of radiation on cells has been found to be dependent on the dosage of the radiation, the location of the cell in regards to tissue, and whether the cell is a somatic or germ line cell. Generally, ionizing radiation appears to reduce methylation of DNA in cells.

Metal transporter CNNM3 is a human transmembrane protein which is made up of 707 amino acids. Although CNNM3 is ubiquitous, it is mostly present in the kidney, brain, lung, spleen, heart and liver.

<span class="mw-page-title-main">Robert Clarke (academic)</span> Northern Irish oncology researcher

Robert Clarke is a Northern Irish oncology researcher and academic administrator. He is the executive director of The Hormel Institute, a professor of biochemistry, Molecular Biology and Biophysics at the University of Minnesota, and an Adjunct Professor of Oncology at Georgetown University.

Endocrine therapy is a common treatment for estrogen receptor positive breast cancer. However, resistance to this therapy can develop, leading to relapse and progression of disease. This highlights the need for new strategies to combat this resistance.

References

  1. 1 2 3 Alfarouk, KO; Stock, CM; Taylor, S; Walsh, M; Muddathir, AK; Verduzco, D; Bashir, AH; Mohammed, OY; Elhassan, GO; Harguindey, S; Reshkin, SJ; Ibrahim, ME; Rauch, C (2015). "Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp". Cancer Cell International. 15: 71. doi:10.1186/s12935-015-0221-1. PMC   4502609 . PMID   26180516.
  2. 1 2 3 4 5 6 7 8 9 10 11 Luqmani, Y.A. (2005). "Mechanisms of Drug Resistance in Cancer Chemotherapy". Medical Principles and Practice. 14 (1): 35–48. doi: 10.1159/000086183 . PMID   16103712.
  3. ↑ Marusyk, Andriy; Polyak, Kornelia (2010-01-01). "Tumor heterogeneity: causes and consequences". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1805 (1): 105–17. doi:10.1016/j.bbcan.2009.11.002. ISSN   0006-3002. PMC   2814927 . PMID   19931353.
  4. ↑ DeMichele A, Yee D, Esserman L (2017). "Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer". N Engl J Med. 377 (23): 2287–2289. doi:10.1056/NEJMcibr1711545. PMID   29211674. S2CID   205067431.
  5. ↑ "The Genetics of Cancer". National Cancer Institute. 22 April 2015. Retrieved 25 February 2016.
  6. 1 2 3 Albertson, Donna G. (2006-08-01). "Gene amplification in cancer". Trends in Genetics. 22 (8): 447–455. doi:10.1016/j.tig.2006.06.007. ISSN   0168-9525. PMID   16787682.
  7. ↑ Ma, C.; Martin, S.; Trask, B.; Hamlin, J. L. (1993-04-01). "Sister chromatid fusion initiates amplification of the dihydrofolate reductase gene in Chinese hamster cells". Genes & Development. 7 (4): 605–620. doi: 10.1101/gad.7.4.605 . ISSN   0890-9369. PMID   8458577.
  8. ↑ Gorlick, Richard; Goker, Erdem; Trippett, Tanya; Waltham, Mark; Banerjee, Debabrata; Bertino, Joseph R. (1996-10-03). "Intrinsic and acquired resistance to methotrexate in acute leukemia". N. Engl. J. Med. 335 (14): 1041–1048. doi:10.1056/NEJM199610033351408. PMID   8793930.
  9. ↑ Wang, Tian-Li; Diaz, Luis A.; Romans, Katharine; et al. (2004-03-02). "Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients". Proceedings of the National Academy of Sciences of the United States of America. 101 (9): 3089–3094. Bibcode:2004PNAS..101.3089W. doi: 10.1073/pnas.0308716101 . ISSN   0027-8424. PMC   420348 . PMID   14970324.
  10. ↑ Gorre, M. E.; Mohammed, M.; Ellwood, K.; et al. (2001-08-03). "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification". Science. 293 (5531): 876–880. doi: 10.1126/science.1062538 . ISSN   0036-8075. PMID   11423618. S2CID   1279564.
  11. ↑ Uncovering a new principle in chemotherapy resistance in breast cancer July 20, 2016, NCI Press Office, retrieved 7 December 2017
  12. 1 2 3 4 5 6 7 Housman, Genevieve; Byler, Shannon; Heerboth, Sarah; Lapinska, Karolina; Longacre, Mckenna; Snyder, Nicole; Sarkar, Sibaji (2014-09-05). "Drug Resistance in Cancer: An Overview". Cancers. 6 (3): 1769–1792. doi: 10.3390/cancers6031769 . PMC   4190567 . PMID   25198391.
  13. ↑ Kantharidis, Phillip; El-Oska, Assam; de Silva, Michelle; et al. (November 1997). "Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance". Clinical Cancer Research. 3 (11): 2025–2032. PMID   9815593.
  14. ↑ Worm, J.; Kirkin, A. F.; Dzhandzhugazyan, K. N.; Guldberg, P. (2001-10-26). "Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells". The Journal of Biological Chemistry. 276 (43): 39990–40000. doi: 10.1074/jbc.M103181200 . ISSN   0021-9258. PMID   11509559.
  15. ↑ Christmann, Markus; Pick, Matthias; Lage, Hermann; et al. (2001-04-01). "Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene mgmt". International Journal of Cancer. 92 (1): 123–129. doi:10.1002/1097-0215(200102)9999:9999<::aid-ijc1160>3.3.co;2-m. ISSN   1097-0215. PMID   11279615.
  16. ↑ Al-Jamal, Hamid A. N.; Jusoh, Siti Asmaa Mat; Yong, Ang Cheng; et al. (2014-01-01). "Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells". Asian Pacific Journal of Cancer Prevention. 15 (11): 4555–4561. doi: 10.7314/apjcp.2014.15.11.4555 . ISSN   1513-7368. PMID   24969884.
  17. ↑ Mickley, L A; Spengler, B A; Knutsen, T A; Biedler, J L; Fojo, T (1997-04-15). "Gene rearrangement: a novel mechanism for MDR-1 gene activation". Journal of Clinical Investigation. 99 (8): 1947–1957. doi:10.1172/jci119362. PMC   508019 . PMID   9109439.
  18. ↑ Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold; et al. (2000-03-28). "Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo". Proceedings of the National Academy of Sciences. 97 (7): 3473–3478. Bibcode:2000PNAS...97.3473H. doi: 10.1073/pnas.97.7.3473 . ISSN   0027-8424. PMC   16264 . PMID   10716719.
  19. 1 2 Bentires-Alj, Mohamed; Barbu, Veronique; Fillet, Marianne; Chariot, Alain; Relic, Biserka; Jacobs, Nathalie; Gielen, Jacques; Merville, Marie-Paule; Bours, Vincent (2003-01-01). "NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells". Oncogene. 22 (1): 90–97. doi: 10.1038/sj.onc.1206056 . ISSN   0950-9232. PMID   12527911.
  20. ↑ Kim, Hyung Gyun; Hien, Tran Thi; Han, Eun Hee; Hwang; et al. (2011-03-01). "Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation". British Journal of Pharmacology. 162 (5): 1096–1108. doi:10.1111/j.1476-5381.2010.01101.x. ISSN   1476-5381. PMC   3051382 . PMID   21054339.
  21. ↑ Thévenod, Frank; Friedmann, Jenny M.; Katsen, Alice D.; Hauser, Ingeborg A. (2000-01-21). "Up-regulation of Multidrug Resistance P-glycoprotein via Nuclear Factor-κB Activation Protects Kidney Proximal Tubule Cells from Cadmium- and Reactive Oxygen Species-induced Apoptosis". Journal of Biological Chemistry. 275 (3): 1887–1896. doi: 10.1074/jbc.275.3.1887 . ISSN   0021-9258. PMID   10636889.
  22. ↑ Kuo, Macus Tien; Liu, Zesheng; Wei, Yingjie; et al. (2002-03-27). "Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling". Oncogene. 21 (13): 1945–1954. doi:10.1038/sj.onc.1205117. ISSN   0950-9232. PMID   11960367.
  23. ↑ Zhou, Ge; Kuo, M. Tien (1997-06-13). "NF-κB-mediated Induction of mdr1b Expression by Insulin in Rat Hepatoma Cells". Journal of Biological Chemistry. 272 (24): 15174–15183. doi: 10.1074/jbc.272.24.15174 . ISSN   0021-9258. PMID   9182539.
  24. ↑ Gerson, Stanton L. (2004). "MGMT: its role in cancer aetiology and cancer therapeutics". Nature Reviews Cancer. 4 (4): 296–307. doi:10.1038/nrc1319. PMID   15057289. S2CID   6591417.
  25. ↑ Burger, H.; Nooter, K.; Boersma, A. W.; van Wingerden, K. E.; Looijenga, L. H.; Jochemsen, A. G.; Stoter, G. (1999-05-17). "Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines". International Journal of Cancer. 81 (4): 620–628. doi:10.1002/(sici)1097-0215(19990517)81:4<620::aid-ijc19>3.0.co;2-s. ISSN   0020-7136. PMID   10225454.
  26. ↑ Youn, Cha-Kyung; Kim, Mi-Hwa; Cho, Hyun-Ju; et al. (2004-07-15). "Oncogenic H-Ras Up-Regulates Expression of ERCC1 to Protect Cells from Platinum-Based Anticancer Agents". Cancer Research. 64 (14): 4849–4857. doi:10.1158/0008-5472.CAN-04-0348. ISSN   0008-5472. PMID   15256455.
  27. ↑ Messina, Samantha; Leonetti, Carlo; De Gregorio, Giorgia; et al. (2004-07-23). "Ras inhibition amplifies cisplatin sensitivity of human glioblastoma". Biochemical and Biophysical Research Communications. 320 (2): 493–500. doi:10.1016/j.bbrc.2004.06.003. PMID   15219856.
  28. ↑ Miyashita, T; Reed, JC (January 1, 1993). "Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line". Blood. 81 (1): 151–7. doi: 10.1182/blood.V81.1.151.151 . PMID   8417786.
  29. 1 2 Clarke, Robert; Liu, Minetta C.; Bouker, Kerrie B.; et al. (2003-01-01). "Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling". Oncogene. 22 (47): 7316–7339. doi: 10.1038/sj.onc.1206937 . ISSN   0950-9232. PMID   14576841.
  30. ↑ Nardi, Valentina; Azam, Mohammad; Daley, George Q. (2004-01-01). "Mechanisms and implications of imatinib resistance mutations in BCR-ABL". Current Opinion in Hematology. 11 (1): 35–43. doi:10.1097/00062752-200401000-00006. ISSN   1065-6251. PMID   14676625. S2CID   43330618.
  31. 1 2 Ganapathi, Ram; Ganapathi, Mahrukh K. (2013-01-01). "Mechanisms regulating resistance to inhibitors of topoisomerase II". Frontiers in Pharmacology. 4: 89. doi: 10.3389/fphar.2013.00089 . PMC   3729981 . PMID   23914174.
  32. ↑ Schröder, Carolina P.; Godwin, Andrew K.; O'dwyer, Peter J.; et al. (1996-01-01). "Glutathione and Drug Resistance". Cancer Investigation. 14 (2): 158–168. doi:10.3109/07357909609018891. ISSN   0735-7907. PMID   8597901.
  33. ↑ Conze, D.; Weiss, L.; Regen, P. S.; et al. (2001-12-15). "Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells". Cancer Research. 61 (24): 8851–8858. ISSN   0008-5472. PMID   11751408.
  34. 1 2 3 Lee, Soo-Youn; McLeod, Howard L (2011-01-01). "Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application". The Journal of Pathology. 223 (1): 15–27. doi:10.1002/path.2766. ISSN   1096-9896. PMID   20818641. S2CID   6330198.
  35. ↑ Chaudhuri AR…Nussenzweig A. Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells. Nature. July 21, 2016. DOI: 10.1038/nature18325.
  36. ↑ Hoffmann, Katrin; Bekeredjian, Raffi; Schmidt, Jan; et al. (2008). "Effects of the High-Affinity Peptide Reversin 121 on Multidrug Resistance Proteins in Experimental Pancreatic Cancer". Tumor Biology. 29 (6): 351–358. doi:10.1159/000178142. PMID   19039261. S2CID   38476310.
  37. ↑ Li, Yiwei; Ahmed, Fakhara; Ali, Shadan; et al. (2005-08-01). "Inactivation of Nuclear Factor κB by Soy Isoflavone Genistein Contributes to Increased Apoptosis Induced by Chemotherapeutic Agents in Human Cancer Cells". Cancer Research. 65 (15): 6934–6942. doi:10.1158/0008-5472.CAN-04-4604. ISSN   0008-5472. PMID   16061678.
  38. ↑ Liu, Xiangrui; Wilcken, Rainer; Joerger, Andreas C.; et al. (2013-07-01). "Small molecule induced reactivation of mutant p53 in cancer cells". Nucleic Acids Research. 41 (12): 6034–6044. doi:10.1093/nar/gkt305. ISSN   0305-1048. PMC   3695503 . PMID   23630318.
  39. ↑ Xu, W.; Cai, B.; Chen, J.l.; et al. (2008-07-01). "ATP7B antisense oligodeoxynucleotides increase the cisplatin sensitivity of human ovarian cancer cell line SKOV3ipl". International Journal of Gynecological Cancer. 18 (4): 718–722. doi:10.1111/j.1525-1438.2007.01085.x. ISSN   1525-1438. PMID   17944925. S2CID   25948703.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.